Medicare’s controversial draft decision - released on January 11th of this year - to restrict coverage of Aduhelm to beneficiaries who enroll in post-marketing clinical trials may be the only feasible option left for the product. Such a policy is called coverage with evidence development.
Subscribe to:
Post Comments (Atom)
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
Training artificial intelligence models on more diverse image and data sets can augment decision making, overcome knowledge gaps, and promot...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
No comments:
Post a Comment